BRAF and non-small cell lung carcinoma: The current study provides new data concerning BRAF immunohistochemical technique as a reliable methodology for the analysis of the mutational status of BRAF V600E in NSCLC patients especially with the recent development of mutation-specific BRAFV600E monoclonal antibodies which made it a rapid and cost-effective test for those patients.